CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)-Results of an initial safety cohort
dc.contributor.author | Hall, M. | |
dc.contributor.author | Allan, K. | |
dc.contributor.author | Michael, A. | |
dc.contributor.author | Clamp, Andrew R | |
dc.contributor.author | Glasspool, R. | |
dc.contributor.author | Nicum, S. | |
dc.contributor.author | Lord, R. | |
dc.contributor.author | Banerjee, S. N. | |
dc.contributor.author | Roche, J. | |
dc.contributor.author | Stobo, J. | |
dc.contributor.author | Gourley, C. | |
dc.date.accessioned | 2022-11-30T10:21:27Z | |
dc.date.available | 2022-11-30T10:21:27Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Hall M, Allan K, Michael A, Clamp AR, Glasspool R, Nicum S, et al. CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)-Results of an initial safety cohort. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301633. | en |
dc.identifier.doi | 10.1200/JCO.2022.40.16_suppl.5577 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625809 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5577 | en |
dc.title | CeNtuRIOn: Rucaparib (R) with nivolumab (N) and ipilimumab (I) in patients (pts) with relapsed ovarian cancer (ROC)-Results of an initial safety cohort | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Mount Vernon Cancer Centre, Northwood, United Kingdom | en |
dc.identifier.journal | Journal of Clinical Oncology | en |
dc.description.note | en] |